Original Article

International Journal of Impotence Research (2009) 21, 221–227; doi:10.1038/ijir.2009.21; published online 28 May 2009

Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation

A Aversa1, M Pili1, D Francomano1, R Bruzziches1, E Spera2, G La Pera3 and G Spera1

  1. 1Chair of Internal Medicine, DFM, Sapienza University of Rome, Italy
  2. 2Urology Department, Tor Vergata University of Rome, Italy
  3. 3Azienda Ospedaliera San Camillo, Forlanini, Rome, Italy

Correspondence: Professor A Aversa, Department of Medical Pathophysiology, Sapienza University of Rome, Viale Policlinico 155, 00161 Rome, Italy. E-mail: antonio.aversa@uniroma1.it

Received 16 February 2009; Revised 16 April 2009; Accepted 17 April 2009; Published online 28 May 2009.



Premature ejaculation (PE) is thought to be the most common male sexual dysfunction; however, the prevalence of lifelong (LL)-PE is relatively low. The aim of this study was to investigate the effects of on-demand vardenafil (10mg) to modify the intravaginal ejaculatory latency time (IELT) in men with LL-PE without erectile dysfunction. Forty-two men (18–35 years) were enrolled in a 16-week, double-blind, placebo-controlled, cross-over study. Primary end point was the modification from baseline of IELT assessed by stopwatch technique; secondary end points were post-ejaculatory refractory time (PERT) and variations of scores at the Index of Premature Ejaculation questionnaire. The changes in geometric mean IELT were superior after taking vardenafil (0.6±0.3 vs 4.5±1.1min, P<0.01), compared with placebo (0.7±0.3 vs 0.9±1.0min, ns). PERT dropped significantly after vardenafil (16.7±2.0 vs 4.3±0.9min, P<0.001), compared with placebo (15.3±2.2 vs 15.8±2.3min). Patients who took vardenafil (vs placebo) reported significantly (P<0.01) increased ejaculatory control (6±2 vs 16±2), improved overall sexual satisfaction (7±2 vs 15±1) and distress (4±1 vs 8±1) scores, respectively. Multiple regression analysis (r2=0.86) for IELT by the number of attempts at sexual intercourse showed significant differences between the slopes of lines for placebo and vardenafil (P<0.0001). The most common adverse events for vardenafil (vs placebo) were headache (10 vs 3%), flushing (12 vs 0%) and dyspepsia (10 vs 0%), which tended to disappear over the time. In conclusion, in our study, vardenafil increased IELT and reduced PERT in men with LL-PE. Besides, improvements in confidence, perception of ejaculatory control and overall sexual satisfaction were reported.


phosphodiesterase type-5 inhibitor; IELT; PERT; ejaculatory control; treatment



These links to content published by NPG are automatically generated


The etiology and management of premature ejaculation

Nature Clinical Practice Urology Review (01 Sep 2005)

Ejaculatory disorders: pathophysiology and management

Nature Clinical Practice Urology Review (01 Feb 2008)

See all 22 matches for Reviews


Sexual dysfunction Anesthetic spray improves premature ejaculation

Nature Reviews Urology News and Views (01 Sep 2009)

Extra navigation